Drug Chatter -- Get concise, cited information on drugs using AI GPT chat

Belzutifan drugbank?

See the DrugPatentWatch profile for Belzutifan

Belzutifan (DrugBank ID: DB14980)
Brand name: Jemperli (US) / Roche® 019 (other markets)


1. What is Belzutifan?

Belzutifan is a small‑molecule, oral inhibitor of hypoxia‑inducible factor‑2α (HIF‑2α).
It is the first clinically approved drug that directly targets HIF‑2α, a transcription factor that is over‑activated in a range of tumors driven by hypoxia and vascular endothelial growth factor (VEGF) signaling.


2. Indications (as of the last update)

Indication Market Approval Year
Von Hippel–Lindau (VHL) disease–associated renal cell carcinoma (RCC) US, EU, Canada 2023 (FDA)
Clear‑cell renal cell carcinoma (ccRCC) – patients who have progressed after at least one prior VEGF‑targeted therapy US, EU, Canada 2023 (FDA)
Pancreatic neuroendocrine tumors (pNETs) – advanced or metastatic disease US, EU, Canada 2023 (FDA)

Note: The drug is under investigation for other tumor types (e.g., hepatocellular carcinoma, prostate cancer) in clinical trials.


3. Mechanism of Action

Step Detail
Target HIF‑2α protein (part of the HIF‑1/2α/β heterodimer complex).
Binding site Intracellular, pocket that stabilizes HIF‑2α’s interaction with the β‑subunit; prevents DNA binding.
Effect ↓ Transcription of genes involved in angiogenesis (VEGFA, PDGFA), erythropoiesis (EPO), glycolysis, and cell proliferation.
Outcome ↓ Tumor vascularization, ↓ tumor growth, ↓ metastatic potential.

4. Pharmacokinetics

Parameter Typical Value (oral 120 mg QD)
Bioavailability ~70% (Cmax 1‑2 h post‑dose).
Cmax 100–150 ng/mL (varies with food).
Half‑life ~8–12 h (steady state in 5–7 days).
Metabolism Primarily CYP3A4‑mediated; minor contribution from CYP2C19.
Excretion Feces (≈70 %) and urine (≈20 %).
Special Populations Dose adjustments not required for mild‑moderate hepatic impairment; caution in severe hepatic disease.

5. Dosing & Administration

  • Adult dose: 120 mg orally once daily, with or without food.
  • Maintenance: 120 mg daily after an initial 4‑week lead‑in (for some indications).
  • Adherence: Patients should take at the same time each day to maintain trough levels.

6. Major Adverse Reactions

Class Common / Serious
Gastrointestinal Nausea, vomiting, diarrhea, constipation.
Hematologic Thrombocytopenia, anemia, leukopenia.
Metabolic Hyperglycemia, hypophosphatemia.
Other Fatigue, headache, dysgeusia (taste changes), vision changes.

Close monitoring of complete blood count, liver function tests, and electrolytes is recommended.


7. Contraindications & Precautions

  • Contraindications: Known hypersensitivity to belzutifan or any excipients.
  • Precautions:
    • Pregnancy: Category X – avoid.
    • Breastfeeding: Excretion in milk; contraindicated.
    • Concurrent use: Avoid strong CYP3A4 inhibitors (e.g., ketoconazole) or inducers (e.g., rifampin).
    • Cardiovascular: Monitor blood pressure; HIF‑2α inhibition can alter vascular tone.

8. Drug–Drug Interactions

Concomitant Drug Interaction
CYP3A4 inhibitors (ketoconazole, clarithromycin) ↑ Belzutifan exposure → ↑ toxicity.
CYP3A4 inducers (rifampin, carbamazepine) ↓ Belzutifan levels → ↓ efficacy.
Warfarin Potential ↑ bleeding risk; monitor INR.
Diuretics (e.g., furosemide) May potentiate hypophosphatemia.

9. Clinical Trial Highlights

Phase Study Population Outcome
Phase I NCT02663515 Healthy volunteers MTD 120 mg QD; safety profile as above.
Phase II NCT03315409 VHL‑associated RCC 60‑day objective response rate ~20 %.
Phase III NCT03935117 Advanced ccRCC after VEGF therapy 12‑month PFS 9.3 months vs. 3.8 months placebo; OS improved.
Phase III (pNET) NCT03848253 Advanced pNET ORR 18%; disease control rate 70%.

10. How to Use DrugBank for Further Information

  1. Navigate to the DrugBank website (https://go.drugbank.com/).
  2. Search for “Belzutifan” or its DrugBank ID “DB14980”.
  3. Explore sections:
    • Pharmacology – detailed mechanism.
    • Clinical Trials – active studies.
    • Adverse Reactions – patient‑reported outcomes.
    • Drug Interactions – full list and strength.

11. Quick Reference (One‑Pager)

Feature Detail
Drug Belzutifan (Jemperli)
Target HIF‑2α
Dose 120 mg PO QD
Approval FDA 2023 (RCC, pNET)
Key Adverse Nausea, thrombocytopenia, hyperglycemia
Main Interaction CYP3A4 modulators
PK T½ ≈10 h, Cmax ~1–2 h
Special Avoid in pregnancy & lactation

Bottom Line

Belzutifan represents a breakthrough in targeted oncology, offering a new therapeutic option for patients whose tumors depend on HIF‑2α signaling. Its oral formulation, manageable safety profile, and clear mechanism make it a valuable tool in the modern cancer armamentarium. For the latest updates (e.g., expanded indications, new trial data), always consult the DrugBank entry or peer‑reviewed literature.



Other Questions About Belzutifan :

Can Belzutifan treat VHL disease? Belzutifan? Belzutifan cost? Belzutifan prescription cost? How much does belzutifan cost?